Cardiovascular Mortality in Patients With Metastatic Prostate Cancer Exposed to Androgen Deprivation Therapy: A Population-Based Study
- 1 June 2015
- journal article
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 13 (3) , e123-e130
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- The impact of androgen‐deprivation therapy ( ADT ) on the risk of cardiovascular ( CV ) events in patients with non‐metastatic prostate cancer: a population‐based studyBJU International, 2014
- Cardiovascular Morbidity Associated with Gonadotropin Releasing Hormone Agonists and an AntagonistEuropean Urology, 2014
- EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate CancerEuropean Urology, 2014
- The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: An unresolved controversyCritical Reviews in Oncology/Hematology, 2013
- Prostate‐specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentationCancer, 2012
- Contemporary Role of Androgen Deprivation Therapy for Prostate CancerEuropean Urology, 2012
- Prostate cancer in the elderlyCancer, 2011
- Absolute and Relative Risk of Cardiovascular Disease in Men With Prostate Cancer: Results From the Population-Based PCBaSe SwedenJournal of Clinical Oncology, 2010
- Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy: Observational Study of Veterans With Prostate CancerJNCI: Journal of the National Cancer Institute, 2009
- Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate CancerJournal of Clinical Oncology, 2006